<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305563</url>
  </required_header>
  <id_info>
    <org_study_id>CA212-016</org_study_id>
    <nct_id>NCT02305563</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of ulocuplumab in
      combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid
      Leukemia (AML).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business objectives have changed, slow accrual, the standard of care for the patient population
    changed and we were unable to accrue any longer.
  </why_stopped>
  <start_date type="Actual">January 27, 2015</start_date>
  <completion_date type="Actual">June 4, 2019</completion_date>
  <primary_completion_date type="Actual">June 4, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing a ulocuplumab-related dose limiting toxicity (DLT) during the DLT evaluation period based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Grade 3 or higher Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs) leading to discontinuation</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs) leading to death</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Laboratory Abnormalities</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response based on the Rate of Complete Remission (CR/CRi)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort) Complete Remission (CR), Complete Remission with incomplete blood count recovery (CRi), Rate of Complete Remission (CR/CRi)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator assessed best overall response(BOR) using AML response criteria</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 1 (escalation cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) leading to discontinuation</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) leading to death</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Laboratory Abnormalities</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Phase 2 (expansion cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-drug antibody(ADA) positive for ulocuplumab</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed ulocuplumab serum concentration (Tmax)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the ulocuplumab concentration-time curve from time zero to the last quantifiable concentration (AUC(0-T))</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the ulocuplumab concentration-time curve in one dosing interval (AUC{TAU})</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the ulocuplumab concentration-time curve from time zero to infinity (AUC(INF))</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half life (T-HALF)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of ulocuplumab</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in electrocardiogram(ECG) intervals</measure>
    <time_frame>Baseline up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Remission (OR) as determined by investigator assessment using AML response criteria</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete Remission (CR/CRi) as determined by investigator assessment using AML response criteria</measure>
    <time_frame>Up to 30 days after discontinuation of treatment</time_frame>
    <description>Complete Remission (CR), Complete Remission with incomplete blood count recovery (CRi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall survival: Defined as the time between the date of randomization and the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Ulocuplumab + low dose Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulocuplumab Dose A + low dose Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulocuplumab Dose B + low dose Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose Cytarabine only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low Dose Cytarabine only Phase 2 (expansion cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-936564</intervention_name>
    <arm_group_label>Ulocuplumab + low dose Cytarabine</arm_group_label>
    <arm_group_label>Ulocuplumab Dose A + low dose Cytarabine</arm_group_label>
    <arm_group_label>Ulocuplumab Dose B + low dose Cytarabine</arm_group_label>
    <arm_group_label>low dose Cytarabine only</arm_group_label>
    <other_name>Ulocuplumab</other_name>
    <other_name>MDX-1338</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Ulocuplumab + low dose Cytarabine</arm_group_label>
    <arm_group_label>Ulocuplumab Dose A + low dose Cytarabine</arm_group_label>
    <arm_group_label>Ulocuplumab Dose B + low dose Cytarabine</arm_group_label>
    <arm_group_label>low dose Cytarabine only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Newly Diagnosed Acute Myeloid Leukemia (AML)

          -  Considered inappropriate for intensive remission induction therapy by an investigator

          -  Not eligible for stem cell transplantation

        Exclusion Criteria:

          -  Acute promyelocytic leukemia

          -  Current Myelodysplastic syndrome only subjects

          -  Unstable angina or uncontrolled congestive heart failure

          -  Any other malignancy, excluding basal or squamous cell carcinoma of the skin, in situ
             melanoma, cervical carcinoma in situ, localized prostate cancer, or superficial
             bladder cancer stage 0, from which the subject has not been disease-free for at least
             3 years

          -  Respiratory disease requiring continuous supplemental oxygen

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucla Center Health Sci</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-3075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Adult Bone Marrow Transplant Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liga Paranaense De Combate Ao Cancer Erasto Gaertner</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Do Cancer Mae De Deus / Cor Hospital Mae De Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90110-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Pio Xii Hosp Cancer De Barretos</name>
      <address>
        <city>Barretos</city>
        <state>SAO Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SAO Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IEP Sao Lucas</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01236-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04546-004</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tel Aviv</city>
        <zip>94239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milan</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>4600001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fukuyama-shi</city>
        <state>Hiroshima</state>
        <zip>7200001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>2591193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hirakata-shi</city>
        <state>Osaka</state>
        <zip>5731191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>1138677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>1418625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>1900014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Taipei City</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Taipei City</city>
        <zip>25173</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Romania</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 27, 2014</study_first_submitted>
  <study_first_submitted_qc>November 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 3, 2020</submitted>
    <returned>June 23, 2020</returned>
    <submitted>July 17, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

